Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
- 13 October 2004
- journal article
- review article
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 15 (6) , 506-512
- https://doi.org/10.1016/j.copbio.2004.09.001
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell VaccinationClinical Cancer Research, 2004
- Neutralization Assay Using a Modified Vaccinia Virus Ankara Vector Expressing the Green Fluorescent Protein Is a High-Throughput Method To Monitor the Humoral Immune Response against Vaccinia VirusClinical and Vaccine Immunology, 2004
- Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal CarcinomaJournal of Virology, 2004
- Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8+-T-Cell Epitope Derived from the Circumsporozoite Protein ofPlasmodium yoeliiJournal of Virology, 2003
- Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I TrialHuman Gene Therapy, 2003
- Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3LJournal of Virology, 2003
- Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccineJournal of General Virology, 2003
- Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus AnkaraJournal of Virology, 2002
- Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA VaccinesJournal of Virology, 2002
- A Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human PapillomavirusHuman Gene Therapy, 2002